COVID CHAOS - Ep 1 by SurfingMASH published on 2020-07-30T15:19:47Z Navigating NAFLD/NASH clinical trials through the pandemic Dr. Stephen Harrison discusses several ways the pandemic is affecting the planning and execution of clinical trials and our panelists discuss implications for investors, C-suite executives, and forecasters in our first episode, COVID CHAOS: Navigating NAFLD/NASH clinical trials through the pandemic. (FULL TRANSCRIPT: https://bit.ly/COVID-Chaos) Drug developers, investors, researchers, and corporate executives, wrestle weekly to understand what is happening in commercial development of NASH medications. Join hepatology researcher and key opinion leader, Stephen Harrison, star equity analyst, Yasmeen Rahimi, C-suite veteran, Peter Traber, and forecasting and pricing guru, Roger Green, as they discuss the issues affecting the evolving NASH market from their own unique perspectives on this week’s edition of Surfing the NASH Tsunami. Roger Green (00:31): Hi. This is Roger Green, and welcome to the initial podcast of Surfing the NASH Tsunami, a podcast for people who are involved with drug development and commercialization in the liver disease space. We’ve developed this podcast because over the last month we’ve heard tons of questions from virtually everybody involved in this community about the impact of COVID, first, and then how that’s going to affect the entire domino chain of upcoming market events, product readouts, clinical trials, launches, all that going forward. Apple Podcasts: https://bit.ly/NASH-Podcast-Apple Spotify: https://bit.ly/NASH-Podcast-Spotify Stitcher: https://bit.ly/NASH-Podcast-Stitcher Buzzsprout: https://bit.ly/NASH-Podcast-Buzzsprout YouTube: https://bit.ly/NASH-Podcast-YT Genre